Learn more about Aranesp® (darbepoetin alfa) Prescribing Information, including Boxed WARNINGS · Medication Guide · Instructions for Use: Single- Dose. Created to help patients understand why CKD can cause anemia and help guide them through the steps to managing their health. for patients that begins after treatment with Aranesp ® or other erythropoietin protein drugs. Aranesp pre-filled syringe – Patient Information Leaflet (PIL) by Amgen Ltd. It is possible that the leaflet in your medicine pack may differ from this version.
|Published (Last):||4 November 2008|
|PDF File Size:||11.48 Mb|
|ePub File Size:||14.20 Mb|
|Price:||Free* [*Free Regsitration Required]|
If you have any problems, please do not be afraid to ask your doctor or nurse medicxtion help and advice. Aramesp red blood cells have the important job of carrying oxygen around the body. How to store Aranesp 6. What you need to know before you use Aranesp Do not use Aranesp: If you have chronic renal failure Aranesp is used to treat symptomatic anaemia that is associated with chronic renal failure kidney failure in adults and children.
In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
Towards the end of your chemotherapy course, particularly if you have had a lot of chemotherapy, your red blood cell count may fall making you anaemic. If you are receiving chemotherapy Aranesp is used to treat symptomatic anaemia in adult cancer patients with non-bone marrow cancers non-myeloid malignancies who are receiving chemotherapy.
Check that it is the correct dose that your doctor has prescribed.
If you forget to use Aranesp Do not use a double dose to make up for a forgotten dose. If you experience these symptoms you should contact your doctor who will determine the best course of action to treat your anaemia.
A treatment to fit your needs
Active ingredient darbepoetin alfa. If you have any further questions, ask your doctor, pharmacist or nurse. Aranesp is a clear, colourless or slightly pearly solution for injection in a pre-filled syringe. It may harm them, even if their signs of illness are the same as yours. What Is Aranesp Singleject? If you have any signs or symptoms of a severe skin reaction, stop using Aranesp and call your healthcare provider or get medical help right away.
If someone else is injecting for you, they can also use the back of your arms. You know your doctor is in charge of treating your anemia. If you have symptoms which include unusual tiredness and a lack of energy this could mean you have pure red cell aplasia PRCAwhich has been reported in patients. This can happen even if you have never had high blood pressure before. To view the changes to a medicine you must sign up and log in. You can also report side effects directly see details below.
Your normal dialysis routine will not affect the ability of Aranesp to treat your anaemia.
Aranesp pre-filled syringe – Patient Information Leaflet (PIL) – (eMC)
You must stop breast-feeding if you use Aranesp. Leave the pre-filled syringe at room temperature for approximately 30 minutes. Where should I give my injection?
If you are not on dialysis: Disposing of used syringes Do not put the cap back on used needles, as you may accidentally prick yourself. How do I give my injection? The following side effects have been experienced by some patients taking Aranesp: The body needs iron to make red blood cells and carry oxygen. Check the appearance of Aranesp. Injecting Aranesp yourself Your doctor may decide that it is best for you or a carer to inject Aranesp.
If you use more Aranesp than you should You could have serious problems if you use more Aranesp than you need, such as very high blood pressure. If you are a patient with chronic renal failure, and particularly if you do not respond properly to Aranesp, your doctor will check your dose of Aranesp because repeatedly increasing your dose of Aranesp if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
In patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers: